

# HER2-negative Breast Cancer Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/H103E5C66A14EN.html>

Date: March 2022

Pages: 61

Price: US\$ 3,250.00 (Single User License)

ID: H103E5C66A14EN

## Abstracts

HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2. HER2-negative breast cancer means that the people have little or no HER2 protein.

This report contains market size and forecasts of HER2-negative Breast Cancer Treatment in Global, including the following market information:

Global HER2-negative Breast Cancer Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global HER2-negative Breast Cancer Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Chemotherapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of HER2-negative Breast Cancer Treatment include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Pfizer, GlaxoSmithKline, Novartis and Merck and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the HER2-negative Breast Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global HER2-negative Breast Cancer Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global HER2-negative Breast Cancer Treatment Market Segment Percentages, by Type, 2021 (%)

Chemotherapy

Surgery

Radiation

Hormonal therapy/endocrine therapy

Global HER2-negative Breast Cancer Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global HER2-negative Breast Cancer Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Global HER2-negative Breast Cancer Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global HER2-negative Breast Cancer Treatment Market Segment Percentages, By Region and Country, 2021 (%)

## North America

US

Canada

Mexico

## Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

## Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

## South America

Brazil

Argentina

Rest of South America

## Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies HER2-negative Breast Cancer Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies HER2-negative Breast Cancer Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

AstraZeneca

Bristol-Myers Squibb

Eli Lilly

Pfizer

Novartis

Pfizer

GlaxoSmithKline

Novartis

Merck

Eli Lilly

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 HER2-negative Breast Cancer Treatment Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global HER2-negative Breast Cancer Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL HER2-NEGATIVE BREAST CANCER TREATMENT OVERALL MARKET SIZE**

- 2.1 Global HER2-negative Breast Cancer Treatment Market Size: 2021 VS 2028
- 2.2 Global HER2-negative Breast Cancer Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top HER2-negative Breast Cancer Treatment Players in Global Market
- 3.2 Top Global HER2-negative Breast Cancer Treatment Companies Ranked by Revenue
- 3.3 Global HER2-negative Breast Cancer Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 HER2-negative Breast Cancer Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies HER2-negative Breast Cancer Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 HER2-negative Breast Cancer Treatment Players in Global Market
  - 3.6.1 List of Global Tier 1 HER2-negative Breast Cancer Treatment Companies

### 3.6.2 List of Global Tier 2 and Tier 3 HER2-negative Breast Cancer Treatment Companies

## 4 MARKET SIGHTS BY PRODUCT

### 4.1 Overview

4.1.1 by Type - Global HER2-negative Breast Cancer Treatment Market Size Markets, 2021 & 2028

4.1.2 Chemotherapy

4.1.3 Surgery

4.1.4 Radiation

4.1.5 Hormonal therapy/endocrine therapy

### 4.2 By Type - Global HER2-negative Breast Cancer Treatment Revenue & Forecasts

4.2.1 By Type - Global HER2-negative Breast Cancer Treatment Revenue, 2017-2022

4.2.2 By Type - Global HER2-negative Breast Cancer Treatment Revenue, 2023-2028

4.2.3 By Type - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

## 5 SIGHTS BY APPLICATION

### 5.1 Overview

5.1.1 By Application - Global HER2-negative Breast Cancer Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

### 5.2 By Application - Global HER2-negative Breast Cancer Treatment Revenue & Forecasts

5.2.1 By Application - Global HER2-negative Breast Cancer Treatment Revenue, 2017-2022

5.2.2 By Application - Global HER2-negative Breast Cancer Treatment Revenue, 2023-2028

5.2.3 By Application - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

## 6 SIGHTS BY REGION

6.1 By Region - Global HER2-negative Breast Cancer Treatment Market Size, 2021 & 2028

6.2 By Region - Global HER2-negative Breast Cancer Treatment Revenue & Forecasts

6.2.1 By Region - Global HER2-negative Breast Cancer Treatment Revenue, 2017-2022

6.2.2 By Region - Global HER2-negative Breast Cancer Treatment Revenue, 2023-2028

6.2.3 By Region - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America HER2-negative Breast Cancer Treatment Revenue, 2017-2028

6.3.2 US HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.3.3 Canada HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.3.4 Mexico HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe HER2-negative Breast Cancer Treatment Revenue, 2017-2028

6.4.2 Germany HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4.3 France HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4.4 U.K. HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4.5 Italy HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4.6 Russia HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4.7 Nordic Countries HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.4.8 Benelux HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia HER2-negative Breast Cancer Treatment Revenue, 2017-2028

6.5.2 China HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.5.3 Japan HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.5.4 South Korea HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.5.5 Southeast Asia HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.5.6 India HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America HER2-negative Breast Cancer Treatment Revenue, 2017-2028

6.6.2 Brazil HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.6.3 Argentina HER2-negative Breast Cancer Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa HER2-negative Breast Cancer Treatment Revenue, 2017-2028



- 6.7.2 Turkey HER2-negative Breast Cancer Treatment Market Size, 2017-2028
- 6.7.3 Israel HER2-negative Breast Cancer Treatment Market Size, 2017-2028
- 6.7.4 Saudi Arabia HER2-negative Breast Cancer Treatment Market Size, 2017-2028
- 6.7.5 UAE HER2-negative Breast Cancer Treatment Market Size, 2017-2028

## **7 PLAYERS PROFILES**

### **7.1 AstraZeneca**

- 7.1.1 AstraZeneca Corporate Summary
- 7.1.2 AstraZeneca Business Overview
- 7.1.3 AstraZeneca HER2-negative Breast Cancer Treatment Major Product Offerings
- 7.1.4 AstraZeneca HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
- 7.1.5 AstraZeneca Key News

### **7.2 Bristol-Myers Squibb**

- 7.2.1 Bristol-Myers Squibb Corporate Summary
- 7.2.2 Bristol-Myers Squibb Business Overview
- 7.2.3 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Major Product Offerings
- 7.2.4 Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
- 7.2.5 Bristol-Myers Squibb Key News

### **7.3 Eli Lilly**

- 7.3.1 Eli Lilly Corporate Summary
- 7.3.2 Eli Lilly Business Overview
- 7.3.3 Eli Lilly HER2-negative Breast Cancer Treatment Major Product Offerings
- 7.3.4 Eli Lilly HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
- 7.3.5 Eli Lilly Key News

### **7.4 Pfizer**

- 7.4.1 Pfizer Corporate Summary
- 7.4.2 Pfizer Business Overview
- 7.4.3 Pfizer HER2-negative Breast Cancer Treatment Major Product Offerings
- 7.4.4 Pfizer HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
- 7.4.5 Pfizer Key News

### **7.5 Novartis**

- 7.5.1 Novartis Corporate Summary
- 7.5.2 Novartis Business Overview

- 7.5.3 Novartis HER2-negative Breast Cancer Treatment Major Product Offerings
- 7.5.4 Novartis HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
- 7.5.5 Novartis Key News
- 7.6 Pfizer
  - 7.6.1 Pfizer Corporate Summary
  - 7.6.2 Pfizer Business Overview
  - 7.6.3 Pfizer HER2-negative Breast Cancer Treatment Major Product Offerings
  - 7.6.4 Pfizer HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
  - 7.6.5 Pfizer Key News
- 7.7 GlaxoSmithKline
  - 7.7.1 GlaxoSmithKline Corporate Summary
  - 7.7.2 GlaxoSmithKline Business Overview
  - 7.7.3 GlaxoSmithKline HER2-negative Breast Cancer Treatment Major Product Offerings
  - 7.7.4 GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
  - 7.7.5 GlaxoSmithKline Key News
- 7.8 Novartis
  - 7.8.1 Novartis Corporate Summary
  - 7.8.2 Novartis Business Overview
  - 7.8.3 Novartis HER2-negative Breast Cancer Treatment Major Product Offerings
  - 7.8.4 Novartis HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
  - 7.8.5 Novartis Key News
- 7.9 Merck
  - 7.9.1 Merck Corporate Summary
  - 7.9.2 Merck Business Overview
  - 7.9.3 Merck HER2-negative Breast Cancer Treatment Major Product Offerings
  - 7.9.4 Merck HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)
  - 7.9.5 Merck Key News
- 7.10 Eli Lilly
  - 7.10.1 Eli Lilly Corporate Summary
  - 7.10.2 Eli Lilly Business Overview
  - 7.10.3 Eli Lilly HER2-negative Breast Cancer Treatment Major Product Offerings
  - 7.10.4 Eli Lilly HER2-negative Breast Cancer Treatment Revenue in Global Market (2017-2022)

7.10.5 Eli Lilly Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. HER2-negative Breast Cancer Treatment Market Opportunities & Trends in Global Market

Table 2. HER2-negative Breast Cancer Treatment Market Drivers in Global Market

Table 3. HER2-negative Breast Cancer Treatment Market Restraints in Global Market

Table 4. Key Players of HER2-negative Breast Cancer Treatment in Global Market

Table 5. Top HER2-negative Breast Cancer Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global HER2-negative Breast Cancer Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global HER2-negative Breast Cancer Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies HER2-negative Breast Cancer Treatment Product Type

Table 9. List of Global Tier 1 HER2-negative Breast Cancer Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 HER2-negative Breast Cancer Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - HER2-negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - HER2-negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - HER2-negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - HER2-negative Breast Cancer Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global HER2-negative Breast Cancer Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global HER2-negative Breast Cancer Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America HER2-negative Breast Cancer Treatment

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America HER2-negative Breast Cancer Treatment

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. AstraZeneca Corporate Summary

Table 31. AstraZeneca HER2-negative Breast Cancer Treatment Product Offerings

Table 32. AstraZeneca HER2-negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Bristol-Myers Squibb Corporate Summary

Table 34. Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Product Offerings

Table 35. Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Eli Lilly Corporate Summary

Table 37. Eli Lilly HER2-negative Breast Cancer Treatment Product Offerings

Table 38. Eli Lilly HER2-negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Pfizer Corporate Summary

Table 40. Pfizer HER2-negative Breast Cancer Treatment Product Offerings

Table 41. Pfizer HER2-negative Breast Cancer Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Novartis Corporate Summary

Table 43. Novartis HER2-negative Breast Cancer Treatment Product Offerings

Table 44. Novartis HER2-negative Breast Cancer Treatment Revenue (US\$, Mn),

(2017-2022)

Table 45. Pfizer Corporate Summary

Table 46. Pfizer HER2-negative Breast Cancer Treatment Product Offerings

Table 47. Pfizer HER2-negative Breast Cancer Treatment Revenue (US\$, Mn),  
(2017-2022)

Table 48. GlaxoSmithKline Corporate Summary

Table 49. GlaxoSmithKline HER2-negative Breast Cancer Treatment Product Offerings

Table 50. GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue (US\$,  
Mn), (2017-2022)

Table 51. Novartis Corporate Summary

Table 52. Novartis HER2-negative Breast Cancer Treatment Product Offerings

Table 53. Novartis HER2-negative Breast Cancer Treatment Revenue (US\$, Mn),  
(2017-2022)

Table 54. Merck Corporate Summary

Table 55. Merck HER2-negative Breast Cancer Treatment Product Offerings

Table 56. Merck HER2-negative Breast Cancer Treatment Revenue (US\$, Mn),  
(2017-2022)

Table 57. Eli Lilly Corporate Summary

Table 58. Eli Lilly HER2-negative Breast Cancer Treatment Product Offerings

Table 59. Eli Lilly HER2-negative Breast Cancer Treatment Revenue (US\$, Mn),  
(2017-2022)

## List Of Figures

### LIST OF FIGURES

Figure 1. HER2-negative Breast Cancer Treatment Segment by Type in 2021

Figure 2. HER2-negative Breast Cancer Treatment Segment by Application in 2021

Figure 3. Global HER2-negative Breast Cancer Treatment Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global HER2-negative Breast Cancer Treatment Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global HER2-negative Breast Cancer Treatment Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by HER2-negative Breast Cancer Treatment Revenue in 2021

Figure 8. By Type - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 9. By Application - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 10. By Region - Global HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 11. By Country - North America HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 12. US HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 16. Germany HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 17. France HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 24. China HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 28. India HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa HER2-negative Breast Cancer Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE HER2-negative Breast Cancer Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. AstraZeneca HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Bristol-Myers Squibb HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Eli Lilly HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)



Figure 40. Pfizer HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Novartis HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Pfizer HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. GlaxoSmithKline HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Novartis HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Merck HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Eli Lilly HER2-negative Breast Cancer Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: HER2-negative Breast Cancer Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/H103E5C66A14EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H103E5C66A14EN.html>